The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

The World Council of Churches has newly published a discussion document: Good News about HIV Treatment, Cure, and Healing: ...

Marine, not her real name, was considering surgery to deal with intense pain. Three doctors refused to see her before a ...

Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...

People with HIV are more likely to have severe premenstrual syndrome (PMS) symptoms than others, such as: In the United States, about 2% of transgender people make up new HIV diagnoses.

HIV activist Solly Nduku was recently elected to the top civil society position at the South African National Aids Council.